$GBT

Global Blood Therapeutics Inc.

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$68.48 ▼-0.015%

Extented Hours

VOLUME

3,279,961

DAY RANGE

68.47 - 68.49

52 WEEK

0 - 68.49

Join Discuss about GBT with like-minded investors

profile
@dros #droscrew
recently

RECAP 8/10 Unusual Calls: $TGT Aug12 175 C $GBT Dec 70 C $DIS Sep 120 C $PAYO Aug 5 C $AA Sep 65 C $RIVN Oct 45 C $COIN Jan 520 C RECAP 8/10 Unusual Puts: $V Aug26 195 P $GOOGL Aug 111 P $SNAP Aug 10 P $NKLA Nov 7 P $JNJ Aug12 167.5 P $PLUG Jan 10 P

78 Replies 12 👍 6 🔥

profile
@Pal #droscrew
recently

$PFE in advanced talks to buy $GBT for ~$5B according to WSJ

45 Replies 12 👍 9 🔥

profile
@dros #droscrew
recently

RECAP 8/4 Unusual Calls: $MQ Sep 10 C $TEVA Jan 12 C $NFLX Sep 260 C $HST Aug 18 C $GBT Sep 50 C $OPEN Aug05 5 C RECAP 8/4 Unusual Puts: $CNQ Dec 50 P $WFC Jan-24 42.5 P $GERN Jan1 P

93 Replies 6 👍 13 🔥

profile
@dros #droscrew
recently

+Initiations 3/28: $ALBO $ASND $BBAI $BEP $BTCS $DRCT $GBT $GMED $HTZ NUVA $OBSV $ONCR $RBLX $SPIR $TCB $TCN $U

71 Replies 15 👍 12 🔥

profile
@Troydeen29 #FOREX
recently

goodnight everyone. I will try to sleep soon and will start my trading tomorrow 9am GBT precisely ;)

85 Replies 6 👍 14 🔥

profile
@ivtrades-Chris #ivtrades
recently

$GBT almost halved

130 Replies 15 👍 15 🔥

profile
@dros #droscrew
recently

yeah GBT picking up nicely matt

86 Replies 15 👍 9 🔥

profile
@RedSunCap #droscrew
recently

GBT looking like fire

125 Replies 11 👍 8 🔥

Key Metrics

Market Cap

0

Beta

0

Avg. Volume

0

Shares Outstanding

67.48 M

Yield

0%

Public Float

0

Next Earnings Date

Next Dividend Date

Company Information

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.

CEO: Ted Love

Website:

HQ: 181 Oyster Point Blvd South San Francisco, 94080 California

Related News